Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PD-L1
Biotech
Instil's licensed PD-L1xVEGF bispecific shows promise in China
Tumors diminished in 62% of patients with advanced non-small cell lung cancer given IMM2510, instilling hope for an upcoming U.S. trial.
Darren Incorvaia
Jul 31, 2025 2:10pm
Instil refills pipeline in $2B biobucks deal with ImmuneOnco
Aug 1, 2024 10:19am
Tracon winds down weeks after injectable PD-L1 inhibitor fails
Jul 31, 2024 9:01am
Incyte drops two PD-L1 drugs as part of 2nd pipeline clear-out
Jul 30, 2024 8:14am
Moderna plants new cancer vaccine trials, weeds PD-L1 work
May 2, 2024 11:00am
Combo may offer route back for Agenus' cervical cancer drug
Jan 23, 2023 10:47am
